<DOC>
	<DOCNO>NCT01975051</DOCNO>
	<brief_summary>We hypothesize PKDL develop SSG well Miltefosine mono-therapy VL ; anti-inflammatory cytokine IL-10 , TGF-β , serum lipid play key role pathogenesis &amp; PKDL patient genetically predispose ; diagnostic tool base immunofluorescence technique sensitive slit skin examination diagnosis PKDL .</brief_summary>
	<brief_title>A Study Explore Association Treatment Regimens Visceral Leishmaniasis , Host Immunological , Genetical Nutrition Factors With Post-kala-azar Dermal Leishmaniasis ( PKDL )</brief_title>
	<detailed_description>Background : Post-kala-azar dermal leishmaniasis skin disorder cause Leishmania donovani usually develop treatment visceral leishmaniasis . The public health importance condition play inter-epidemic reservoir visceral leishmaniasis.It believe condition associate sodium stibogluconate ( SSG ) monotherapy visceral leishmaniasis ; however evidence lack support . Further study carry explore pathogenesis PKDL Bangladesh . Also information available relate development PKDL treatment VL miltefosine monotherapy Bangladesh.Better knowledge pathogenesis PKDL help predict design intervention prevent development PKDL . This help reduce number inter-epidemic reservoir VL hence contribute national kala-azar elimination program . Objectives:1 . To investigate incidence PKDL SSG Miltefosine mono-therapy VL ; 2 . To investigate serum level IL-10 , TGF-β marker lipid metabolism ( serum cholesterol ) treatment PKDL ; 3 . To investigate mRNA expression IL-10 , TGF-β skin lesion PKDL ; 4 . To investigate association gene polymorphism IL-10 , TGF-β PKDL ; 5 . To develop new diagnostic tool diagnosis PKDL detection LD antigen skin tissue punch biopsy use immunofluorescence technique ; , 6 . To investigate leishmania antigen anti-leishmania antibody urine treatment PKDL evaluate possibility use diagnostic tool . Methods:1 . The incidence PKDL treatment VL investigate study retrospective cohort identify cross-sectional survey ; 2. serum level cytokine lipid profile measure respectively cytometric bed-array autoanalyzer treatment PKDL ; 3. mRNA expression cytokine measure real-time PCR treatment PKDL ; 4. gene polymorphism investigate DNA sequence ; 5. new diagnostic tool develop use immunofluorescence technique ; , 6. urine antigen antibody detect ELISA .</detailed_description>
	<mesh_term>Leishmaniasis</mesh_term>
	<mesh_term>Leishmaniasis , Visceral</mesh_term>
	<mesh_term>Miltefosine</mesh_term>
	<criteria>History Visceral Leishmaniasis Presence hypopigmented rash Rk39 strip test positive Written inform consent participant Any medical condition may affect safety patient study procedure Any condition comprises ability comply study procedure Presence splenomegaly Posotive skin smear mycobacterium leprae Positive skin smear fungus Pregnancy test positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Kala- azar</keyword>
	<keyword>PKDL</keyword>
	<keyword>Treatment</keyword>
	<keyword>Pathogenesis</keyword>
	<keyword>Bangladesh</keyword>
</DOC>